Richard H. Haubrich, M.D.
Curriculum Vitae
June 05, 2013
Office
Antiviral Research Center
University of California, San Diego
Department of Medicine
Division of Infectious Diseases
220 Dickinson Street, Suite A
San Diego, CA 92103-8208
Telephone
Fax
E-Mail
(619) 543-8080
(619) 543-5066
rhaubrich@ucsd.edu
Education
1975-1979
1979-1983
1983-1984
1984-1986
1986-1987
1987-1990
B.A. in Chemistry, Occidental College; Los Angeles, CA
M.D., University of Southern California School of Medicine; Los Angeles, CA
Intern, Mercy Hospital and Medical Center; San Diego, CA
Resident, Internal Medicine, Mercy Hospital and Medical Center; San Diego, CA
Chief Resident, Mercy Hospital and Medical Center; San Diego, CA
Fellow, Infectious Diseases, University of Massachusetts Medical Center;
Worcester, MA
Board Certification
1987
1990
American Board of Internal Medicine
American Board of Internal Medicine, Subspecialty Infectious Disease
Honors / Awards
1975-1979
1975-1979
1978
1978-1979
1979-1983
1982
1990
California State Scholarship (undergraduate)
Occidental College Scholarships (undergraduate)
Phi Beta Kappa (undergraduate)
ARCS Scholarship (undergraduate)
State Graduate Fellowship (medical school)
AOA (medical school)
Maxwell Finland Young Investigators Award (post graduate)
Academic Appointments
1987-1988
Instructor in Medicine; Department of Medicine, University of California, San
Diego, CA
1988-1990
Instructor in Medicine; Department of Medicine, University of Massachusetts
Medical Center, Worcester, MA
1990-1991
Assistant Professor of Medicine; Department of Medicine, University of
Massachusetts Medical Center, Worcester, MA
Richard H. Haubrich, M.D.
Curriculum Vitae
Page 2
1991-1998
Assistant Clinical Professor of Medicine; Department of Medicine, Division of
Infectious Diseases, University of California, San Diego, CA
1998-2005
Associate Professor of Medicine; Department of Medicine, Division of Infectious
Diseases, University of California, San Diego, CA
2005-present Professor of Medicine; Department of Medicine, Division of Infectious Diseases,
University of California, San Diego, CA
Current Regional and National Committees / Service
2002-present Co-Director, UCSD Center for AIDS Research Clinical Investigation Core
2003-present Principal Investigator, California Collaborative Treatment Group (CCTG) (a three
center collaborative research organization)
2009-present ACTG Antiretroviral Therapy Strategy (ARTS, previously Optimization of
Antiretroviral Therapy (OpART)) Research Agenda Committee (Ex-Officia Chair
2012, Chair 2009-11, Vice-Chair 2007-09; Member, 2003-present)
2011- present Member, Hepatitis Transformative Science Group, ACTG
Research Interests
Since 1991, Dr. Haubrich has been conducting clinical research with the ACTG (AIDS Clinical
Trial Group, funded by the National Institutes of Health) and the CCTG (California
Collaborative Treatment Group, funded by the California HIV AIDS Research Program). Dr.
Haubrich’s research focuses on antiretroviral therapy for treatment-naive and treatmentexperienced patients, HIV drug resistance and trends in HIV therapy and drug resistance.
Publications
Swerdlow N, Haubrich R. Aggressive treatment of a patient with the acquired immunedeficiency syndrome (Letter). Ann Intern Med 1987;107(4):597.
Richard H. Haubrich, M.D.
Curriculum Vitae
Page 3
1.
2.
Haubrich RH, Keroack MA. Pneumococcal crepitant cellulitis caused by a bronchocutaneous fistula. Chest 1992;101(2):566-567.
3.
Haubrich RH, Takeda A, Koff W, Smith G, Ennis FA. Studies of antibody-dependent
enhancement of human immunodeficiency virus (HIV) type 1 infection mediated by Fc
receptors using sera from recipients of a recombinant gp160 experimental HIV-1 vaccine.
J Infect Dis 1992;165(3):545-548.
4.
Haubrich RH, Bozzette SA. Fluconazole. In: Dollery C, ed. Therapeutic Drugs:
Supplement 1. New York, NY: Churchill Livingstone; 1992:S1.90-S1.94.
5.
Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelli C, Liou S-H, Brown M,
Volberding PA, Crumpacker CS, Beall G, Sacks HS, Merigan TC, Beltangady M,
Smaldone L, Dolin R and the NIAID AIDS Clinical Trials Group (Haubrich RH). A
controlled trial comparing continued zidovudine with didanosine in human
immunodeficiency virus infection. N Engl J Med 1992;327(9):581-587.
6.
Haubrich RH, Haghighat D, Bozzette SA, Tilles J, McCutchan JA, for the California
Collaborative Treatment Group. High-dose fluconazole for treatment of cryptococcal
disease in patients with human immunodeficiency virus infection. J Infect Dis 1994;
170(1):238-242.
7.
Bozzette SA, Finkelstein DM, Spector SA, Frame P, Powderly WG, He W, Phillips L,
Craven D, van der Horst C, Feinberg J, for the NIAID AIDS Clinical Trial Group
(Haubrich RH). A randomized trial of three antipneumocystis agents in patients with
advanced human immunodeficiency virus infection. N Engl J Med 1995;332(11):693-699.
8.
Powderly WG, Finkelstein D, Feinberg J, Frame P, He W, van der Horst C, Koletar SL,
Eyster E, Carey J, Waskin H, Hooton T, Hyslop N, Spector SA, Bozzette SA, for the
NIAID AIDS Clinical Trial Group (Haubrich RH). A randomized trial comparing
fluconazole with clotrimazole troches for the prevention of fungal infections in patients
with advanced human immunodeficiency virus infection. N Engl J Med 1995;332(11):700705.
9.
Haubrich R, McCutchan JA, Holdredge R, Heiner L, Merritt J, Merchant B. An open
label, phase I/II clinical trial to evaluate the safety and biological activity of HIV-IT (V)
(HIV-1IIIBenv/rev retroviral vector) in HIV-1-infected subjects. Hum Gene Ther 1995;
6(7):941-955.
10.
Studies of Ocular Complications of AIDS Research Group in Collaboration with AIDS
Clinical Trials Group (Haubrich RH). Antiviral effects of foscarnet and ganciclovir
therapy on human immunodeficiency virus p24 antigen in patients with AIDS and
cytomegalovirus retinitis. J Infect Dis 1995;172(3):613-621.
11.
Haubrich RH, Flexner C, Lederman MM, Hirsch M, Pettinelli CP, Ginsberg R, Lietman
P, Hamzeh FM, Spector SA, Richman DD, for the AIDS Clinical Trials Group 213 Team.
A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus
nucleoside for human immunodeficiency virus infection. J Infect Dis 1995;172(5):12461252.
Richard H. Haubrich, M.D.
Curriculum Vitae
Page 4
12.
Haubrich R, Warner J, Anderson CG, Merritt J, Jacobsen C, McCutchan JA and the
California Collaborative Treatment Group. Cytotoxic T lymphocyte augmentation using an
HIV-1 env/rev encoding retroviral vector (HIV-IT(V)) as therapy for HIV. Gene Ther
1995;2:599-600.
13.
Warner JF, Jolly D, Mento S, Galpin J, Haubrich R, Merritt J. Retroviral vectors for HIV
immunotherapy. Ann N Y Acad Sci 1995;772:105-116.
14.
Witt MD, Lewis RJ, Larsen RA, Milefchik EN, Leal MA, Haubrich RH, Richie JA,
Edwards JE Jr, Ghannoum MA. Identification of patients with acute AIDS-associated
cryptococcal meningitis who can be effectively treated with fluconazole: the role of
antifungal susceptibility testing. Clin Infect Dis 1996;22(2):322-328.
15.
Torriani FJ, Behling CA, McCutchan JA, Haubrich RH, Havlir DV. Disseminated
Mycobacterium avium complex: correlation between blood and tissue burden. J Infect Dis
1996;173(4):942-949.
16.
Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH,
Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC, for the AIDS
Clinical Trials Group Study 175 Study Team. A trial comparing nucleoside monotherapy
with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per
cubic millimeter. N Engl J Med 1996;335(15):1081-1090.
17.
Haubrich R, Warner J, Anderson CG, Peters G, Merritt J, Jacobsen C, McCutchan JA and
the California Collaborative Treatment Group. Immunotherapy for HIV-1 using an HIV-1
IIIB env/rev encoding retroviral vector [HIV-IT(V)]. In: Gene Delivery Systems. Published
in OECD World Conference Proceedings; 1996:323-334.
18.
Haubrich RH, Saag MS. Management of HIV-associated fungal diseases. Improving the
Management of HIV Disease (Published by the International AIDS Society—USA) 1997;
4(5):10-14.
19.
Fischl MA, Richman DD, Flexner C, Para MF, Haubrich R, Karim A, Yeramian P,
Holden-Wiltse J, Meehan PM. Phase I/II study of the toxicity, pharmacokinetics, and
activity of the HIV protease inhibitor SC-52151. J Acquir Immune Defic Syndr Hum
Retrovirol 1997;15(1):28-34.
20.
Haubrich R. Advances in the diagnosis and monitoring of HIV disease. HIV Update:
Guidelines and Beyond. Published in Conference Proceedings; 1997:3-9.
Richard H. Haubrich, M.D.
Curriculum Vitae
Page 5
21.
Haubrich R, Lalezari J, Follansbee SE, Gill M J, Hirsch M, Richman D, Mildvan D,
Burger HU, Beattie D, Donatacci L, Salgo MP, and the NV14256 Study Team. Improved
survival and reduced clinical progression in HIV-infected patients with advanced disease
treated with saquinavir plus zalcitabine. Antivir Ther 1998;3:33-42.
22.
Metzgar D, Field D, Haubrich R, Wills C. Sequence analysis of a compound codingregion microsatellite in Candida albicans resolves homoplasies and provides a highresolution tool for genotyping. Fems Immunol Med Microbiol 1998;20(2):103-109.
23.
Havlir DV, Haubrich R, Hwang J, Dunne MW, Currier J, Forthal D, Torriani F, Richman
DD, McCutchan JA, for the California Collaborative Treatment Group. Human
immunodeficiency virus replication in AIDS patients with Mycobacterium avium complex
bacteremia: a case control study. J Infect Dis 1998;177:595-599.
24.
El-Sadr WM, Murphy RL, Yurik TM, Luskin-Hawk R, Cheung TW, Balfour Jr. HH, Eng
R, Hooton TM, Kerkering TM, Schultz M, van der Horst C, Hafner R, for the Community
Program for Clinical Research on AIDS and the AIDS Clinical Trials Group (Haubrich
R). Atovaquone compared with dapsone for the prevention of Pneumocystis Carinii
pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides,
or both. N Engl J Med 1998;339(26):1889-1895.
25.
Metzgar D, van Belkum A, Field D, Haubrich R, Wills C. Random amplification of
polymorphic DNA and microsatellite genotyping of pre- and posttreatment isolates of
Candida spp. from human immunodeficiency virus-infected patients on different
fluconazole regimens. J Clin Microbiol 1998;36(8):2308-2313. PMC105037
26.
Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SSC. The effect of six months
treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex
steroids, body composition and muscle strength in age-advanced men and women. Clin
Endocrinol (Oxf.) 1998;49(4):421-432.
27.
Haubrich R, Richman D. Nevirapine, didanosine, and zidovudine for patients with HIV:
the INCAS trial (Letter). JAMA 1999;281(2):130-131.
28.
Revicki DA, Swartz C, Wu AW, Haubrich R, Collier AC. Quality of life outcomes of
saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with
advanced HIV infection with CD4 counts between 50 and 300 cells/mm3. Antivir Ther
1999;4:35-44.
29.
Haubrich RH, Havlir D. Nelfinavir. In: Dolin R, Masur H, Saag MS, eds. AIDS Therapy.
Churchill Livingstone; 1999:177-187.
30.
Haubrich RH, Little SJ, Currier JS, Forthal DN, Kemper CA, Beall GN, Johnson D, Dubé
MP, Hwang JY, McCutchan JA, and the California Collaborative Treatment Group. The
value of patient-reported adherence to antiretroviral therapy in predicting virologic and
immunologic response. AIDS 1999;13(9):1099-1107.
31.
Forthal DN, Landucci G, Haubrich R, Keenan B, Kuppermann BD, Tilles JG, Kaplan J.
Antibody-dependent cellular cytotoxicity independently predicts survival in severely
immunocompromised human immunodeficiency virus-infected patients. J Infect Dis 1999;
180:1338-1341.
Richard H. Haubrich, M.D.
Curriculum Vitae
Page 6
32.
Haubrich R, Thompson M, Schooley R, Lang W, Stein A, Sereni D, van der Ende ME,
Antunes F, Richman D, Pagano G, Kahl L, Fetter A, Brown DJ, Clumeck N, and the
Amprenavir PROAB2002 Study Team. A phase II safety and efficacy study of amprenavir
in combination with zidovudine and lamivudine in HIV-infected patients with limited
antiretroviral experience. AIDS 1999;13(17):2411-2420.
33.
Sha BE, Johnson VA, Kendall MA, Haubrich R, Nokta M, Lamb K, Zackin RA, Nail CD,
Currier JS. Absence of virological changes after acute febrile illnesses in two patients with
undetectable pre-illness plasma HIV-1-RNA levels. AIDS 2000;14(6):746-748.
34.
Günthard HF, Wong JD, Spina CA, Ignacio C, Kwok S, Christopherson C, Hwang J,
Haubrich R, Havlir D, and Richman DD. Effect of influenza vaccination on viral
replication and immune response in persons infected with human immunodeficiency virus
receiving potent antiretroviral therapy. J Infect Dis 2000;181:522-531.
35.
Gulick RM, Hu XJ, Fisus SA, Fletcher CV, Haubrich R, Cheng H, Acosta E, Lagakos
SW, Swanstrom R, Freimuth W, Snyder S, Mills C, Fischl M, Pettinelli C, Katzenstein D,
for the AIDS Clinical Trials Group Study 359 Protocol Team. Randomized study of
saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human
immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical
Trials Group Study 359. J Infect Dis 2000;182:1375-1384.
36.
Moss NE, Lemp G, Blumenthal R, Goldsmith MA, Haubrich R, Kahn JO. From the cell to
the community: AIDS research in California. West J Med 2000;173:119-124. PMC1071020
37.
Lederman MM, McKinnis R, Kelleher D, Cutrell A, Mellors J, Neisler M, Cooney E, Haas
DW, Haubrich R, Stanford J, Horton J, Landay A, Spreen W. Cellular restoration in HIV
infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive
CD4 cell count increase. AIDS 2000;14(17):2635-2642.
38.
Haubrich RH. Structured treatment interruptions: review of current data. Top HIV Med
2000;8(7):9-13.
39.
Fletcher CV, Acosta EP, Cheng H, Haubrich R, Fischl M, Raasch R, Mills C, Hu XJ,
Katzenstein D, Remmel RP, Gulick RM, for the ACTG 884 Protocol Team. Competing
drug-drug interactions among multidrug antiretroviral regimens used in the treatment of
HIV-infected subjects: ACTG 884. AIDS 2000;14(16):2495-2501.
40.
Katzenstein DA, Hughes M, Albrecht M, Hammer S, Para M, Murphy R, Valdez H,
Haubrich R, Liou S, for the ACTG 302 Study Team. Virologic and CD4+ cell responses
to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged
zidovudine treatment of human immunodeficiency virus infection. AIDS Res Hum
Retroviruses 2000;16(11):1031-1037.
41.
Demeter L, Haubrich R. Phenotypic and genotypic resistance assays: methodology,
reliability, and interpretations. J Acquir Immune Defic Syndr 2001;26(Suppl 1):S3-S9.
42.
Haubrich R, Demeter L. Clinical utility of resistance testing: retrospective and prospective
data supporting use and current recommendations. J Acquir Immune Defic Syndr 2001;
26(Suppl 1):S51-S59.
Richard H. Haubrich, M.D.
Curriculum Vitae
Page 7
43.
Kemper CA, Witt MD, Keiser PH, Dubé MP, Forthal DN, Leibowitz M, Smith DS, Rigby
A, Hellmann NS, Lie YS, Leedom J, Richman D, McCutchan JA, Haubrich R, and the
California Collaborative Treatment Group #575 Team. Sequencing of protease inhibitor
therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease
inhibitors. AIDS 2001;15(5):609-615.
44.
Haubrich RH, Currier JS, Forthal DN, Beall G, Kemper CA, Johnson D, Dubé MP,
Hwang J, Leedom JM, Tilles J, McCutchan JA, and the California Collaborative Treatment
Group. A randomized study of the utility of human immunodeficiency virus RNA
measurement for the management of antiretroviral therapy. Clin Infect Dis 2001;33:10601068.
45.
McMahon D, Lederman M, Haas DW, Haubrich R, Stanford J, Cooney E, Horton J,
Kelleher D, Ross L, Cutrell A, Lee D, Spreen W, Mellors JW. Antiretroviral activity and
safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive
HIV-1-infected adults. Antivir Ther 2001;6(2):105-114.
46.
Schooley RT, Clumeck N, Haubrich R, Thompson M, Danner SA, van Der Ende ME,
Sereni D, Antunes F, Blake D, Myers RE, Tisdale M, Millard J, Mustafa N, Nacci P. A
dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone
and in combination with abacavir in HIV-infected adults with limited antiretroviral
experience. Antivir Ther 2001;6(2):89-96.
47.
Becker S, Fisher A, Flexner C, Gerber JG, Haubrich R, Kashuba ADM, Luber AD,
Piscitelli SC. Pharmacokinetic parameters of protease inhibitors and the Cmin/IC50 ratio:
call for consensus (Letter). J Acquir Immune Defic Syndr 2001;27(2):210-211.
48.
Eron JJ, Haubrich R, Lang W, Pagano G, Millard J, Wolfram J, Snowden W, Pedneault L,
Tisdale M. A phase II trial of dual protease inhibitor therapy: amprenavir in combination
with indinavir, nelfinavir, or saquinavir. J Acquir Immune Defic Syndr 2001;26(5):458-461.
49.
Sadler BM, Gillotin C, Lou Y, Eron JJ, Lang W, Haubrich R, Stein DS. Pharmacokinetic
study of human immunodeficiency virus protease inhibitors used in combination with
amprenavir. Antimicrob Agents Chemother 2001;45(12):3663-3668. PMC90895
50.
Haubrich R. Improving the utility of phenotype resistance assays: new cut-points and
interpretation. Advanced Studies in Medicine 2001;1(12):486-490.
51.
Back D, Gatti G, Fletcher C, Garaffo R, Haubrich R, Hoetelmans R, Kurowski M, Luber
A, Merry C, Perno C-F. Therapeutic drug monitoring in HIV infection: current status and
future directions. AIDS 2002;16(Suppl 1):S5-S37.
52.
Swindells S, Evans S, Zackin R, Goldman M, Haubrich R, Filler SG, Balfour Jr. HH, for
the AIDS Clinical Trial Group 722 Study Team. Predictive value of HIV-1 viral load on
risk for opportunistic infection. J Acquir Immune Defic Syndr 2002;30(2):154-158.
53.
Mathews WC, Cole J, Ballard C, Colwell B, Haubrich R, Barber E, Lew T. Early adoption
of HIV-1 resistance testing in the San Diego County Ryan White CARE Act Program:
predictors and outcomes. AIDS Patient Care STDs 2002;16(7):337-348.
Richard H. Haubrich, M.D.
Curriculum Vitae
Page 8
54.
Gulick RM, Hu XJ, Fiscus SA, Fletcher CV, Haubrich R, Cheng H, Acosta E, Lagakos
SW, Swanstrom R, Freimuth W, Snyder S, Mills C, Fischl M, Pettinelli C, Katzenstein D,
for the AIDS Clinical Trials Group Protocol 359 Team. Durability of response to treatment
among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials
Group Protocol 359. J Infect Dis 2002;186(5):626-633.
55.
Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Forthal DN, Leedom J,
Leibowitz M, Whitcomb JM, Richman D, McCutchan JA, and the California Collaborative
Treatment Group. The clinical relevance of non-nucleoside reverse transcriptase inhibitor
hypersusceptibility: a prospective cohort analysis. AIDS 2002;16(15):F33-40.
56.
Kemper CA, Haubrich R, Frank I, Dubin G, Buscarino C, McCutchan JA, Deresinski SC,
California Collaborative Treatment Group. Safety and immunogenicity of hepatitis A
vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized,
placebo-controlled trial. J Infect Dis 2003;187(8):1327-1331.
57.
Haubrich RH. International AIDS Society–USA (IAS–USA). Cases on the Web: Current
applications of HIV drug resistance testing. April 11, 2003. http://www.iasusa.org/cow.
58.
Haubrich RH, Havlir DV. Nelfinavir. In: Dolin R, Masur H, Seag MS, eds. AIDS
Therapy. 2nd Ed. Philadelphia: Churchill Livingstone; 2003:212-224.
59.
Miller V, Haubrich R, Kuritzkes DR. Understanding treatment-resistant HIV. The PRN
Notebook 2003;8(2):12-19.
60.
Lalezari JP, DeJesus E, Northfelt DW, Richmond G, Wolfe P, Haubrich R, Henry D,
Powderly W, Becker S, Thompson M, Valentine F, Wright D, Carlson M, Riddler S, Haas
FF, DeMasi R, Sista PR, Salgo M, Delehanty J. A controlled Phase II trial assessing three
doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and
efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
Antivir Ther 2003;8(4):279-287.
61.
Gallant JE, Gerondelis PZ, Wainberg MA, Shulman NS, Haubrich RH, St Clair M, Lanier
ER, Hellmann NS, Richman DD. Nucleoside and nucleotide analogue reverse transcriptase
inhibitors: a clinical review of antiretroviral resistance. Antivir Ther 2003;8(6):489-506.
62.
Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D'Aquila RT, Johnson
VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle
M, McCarty SD, Vella S, Hirsch MS, Merigan TC; for the AIDS Clinical Trials Group 384
Team. Comparison of four-drug regimens and pairs of sequential three-drug regimens as
initial therapy for HIV-1 infection. N Engl J Med 2003;349(24):2304-2315.
63.
Fletcher CV, Jiang H, Brundage RC, Acosta EP, Haubrich R, Katzenstein D, Gulick RM.
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical
Trials Group Study 359. J Infect Dis 2004;189(7):1176-1184.
64.
Haubrich, RH. Resistance and replication capacity assays: clinical utility and
interpretation. Top HIV Med 2004;12(2):52-56.
Richard H. Haubrich, M.D.
Curriculum Vitae
Page 9
65.
Swanstrom R, Bosch RJ, Katzenstein D, Cheng H, Jiang H, Hellmann N, Haubrich R,
Fiscus SA, Fletcher CV, Acosta EP, Gulick RM, for the AIDS Clinical Trials Group
Protocol 359 Team. Weighted phenotypic susceptibility scores are predictive of the HIV-1
RNA response in protease inhibitor-experienced HIV-1-infected subjects. J Infect Dis
2004;190:886-893.
66.
Brun-Vézinet F, Costagliola D, Khaled MA, Calvez V, Clavel F, Clotet B, Haubrich R,
Kempf D, King M, Kuritzkes D, Lanier R, Miller M, Miller V, Phillips A, Pillay D,
Schapiro J, Scott J, Shafer R, Zazzi M, Zolopa A, DeGruttola V. Clinically validated
genotype analysis: guiding principles and statistical concerns. Antivir Ther 2004;
9(4):465-478.
67.
Yasuda JM, Miller C, Currier JS, Forthal DN, Kemper CA, Beall GN, Tilles JG, Capparelli
EV, McCutchan JA, Haubrich RH, and the California Collaborative Treatment Group
(CCTG). The correlation between plasma concentrations of protease inhibitors, medication
adherence and virological outcome in HIV-infected patients. Antivir Ther 2004;9(5)753761.
68.
Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Tilles JG, Forthal DN,
Leedom J, Leibowitz M, McCutchan JA, Richman DD, and the California Collaborative
Treatment Group. A randomized, prospective study of phenotype susceptibility testing
versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS 2005;19(3):295302.
69.
Hawkins T, Geist C, Young B, Giblin A, Mercier RC, Thornton K, Haubrich R.
Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and
protease inhibitor-treated patients. HIV Clin Trials 2005;6(4):187-196.
70.
Goicoechea M, Haubrich R. CD4 lymphocyte percentage versus absolute CD4
lymphocyte count in predicting HIV disease progression: an old debate revisited. J Infect
Dis 2005;192(6):945-947.
71.
Fletcher CV, Testa MA, Brundage RC, Chesney MA, Haubrich R, Acosta EP, Martinez
A, Jiang H, Gulick RM. Four measures of antiretroviral medication adherence and
virologic response in AIDS Clinical Trials Group Study 359. J Acquir Immune Defic Syndr
2005;40(3):301-306.
72.
Best B, Haubrich R. Tipranavir: a protease inhibitor for multi-drug resistant HIV-1.
Expert Opin Investig Drugs 2006;15(1):59-70.
73.
Goicoechea M, Best B, Seefried E, Wagner G, Capparelli E, Haubrich R, and the
California Collaborative Treatment Group (CCTG). Failure of modified directly observed
therapy combined with therapeutic drug monitoring to enhance antiretroviral adherence in
a patient with major depression. AIDS Patient Care STDS 2006;20(4):233-237.
74.
Wagner GJ, Kanouse DE, Golinelli D, Miller LG, Daar ES, Witt MD, Diamond C, Tilles
JG, Kemper CA, Larsen R, Goicoechea M, Haubrich RH, and the California
Collaborative Treatment Group (CCTG). Cognitive-behavioral intervention to enhance
adherence to ART: a randomized controlled trial (CCTG 578). AIDS 2006;20(9):12951302.
Richard H. Haubrich, M.D.
Curriculum Vitae
Page 10
75.
Goicoechea M, Smith DM, Liu L, May S, Tenorio AR, Ignacio CC, Landay A, Haubrich
R. Determinants of CD4+ T-cell recovery during suppressive antiretroviral therapy:
association of immune activation, T-cell maturation markers and cellular HIV-1 DNA. J
Infect Dis 2006;194(1):29-37.
76.
Goicoechea M, Best B, Capparelli E, Haubrich R, for the California Collaborative
Treatment Group. Concurrent use of efavirenz and oxcarbazepine may not affect efavirenz
plasma concentrations (Letter). Clin Infect Dis 2006;43(1):116-117.
77.
Goicoechea M, Best B, Capparelli E, Caperna J, Ballard C, Haubrich R. Therapeutic
ritonavir-boosted atazanavir plasma concentration and concurrent omeprazole use. AIDS
2006;20(16):2127-2128.
78.
Liu H, Miller LG, Hays RD, Wagner G, Golin CE, Hu W, Kahn K, Haubrich R, Kaplan
AH, Wenger NS. A practical method to calibrate self-reported adherence to antiretroviral
therapy. J Acquir Immune Defic Syndr 2006;43(Suppl 1):S104-S112.
79.
Asfour FR, Haubrich R. Resistance to non-nucleoside reverse transcriptase inhibitors. In:
Skowron G, Ogden R, eds. Reverse Transcriptase Inhibitors in HIV/AIDS Therapy.
Totowa, N.J.: Humana Press; 2006:401-424.
80.
May S, Letendre S, Haubrich R, McCutchan JA, Heaton R, Capparelli E, Ellis R. Meeting
practical challenges of a trial involving a multitude of treatment regimens: an example of a
multi-center randomized controlled clinical trial in NeuroAIDS. J Neuroimmune
Pharmacol 2007;2(1):97-104.
81.
Goicoechea M, Vidal A, Capparelli E, Rigby A, Kemper C, Diamond C, Witt MD,
Haubrich R, and the California Collaborative Treatment Group. A computer-based system
to aid in the interpretation of plasma concentrations of antiretrovirals for therapeutic drug
monitoring. Antivir Ther 2007;12(1)55-62.
82.
Bhasin S, Parker RA, Sattler F, Haubrich R, Alston B, Umbleja T, Shikuma CM, and the
AIDS Clinical Trials Group Protocol A5079 Study Team. Effects of testosterone
supplementation on whole body and regional fat mass and distribution in HIV-infected men
with abdominal obesity. J Clin Endocrinol Metab 2007;92(3):1049-1057.
83.
Haubrich R, Berger D, Chiliade P, Colson A, Conant M, Gallant J, Wilkin T, Nadler J,
Pierone G, Saag M, van Baelen B, Lefebvre E and the POWER 2 Study Group. Week 24
efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS
2007;21(6):F11-F18.
84.
Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, Wohrmann A, Katlama
C, Wilkin T, Haubrich R, Cohen C, Farthing C, Jayaweera D, Markowitz M, Ruane P,
Spinosa-Guzman S, Lefebvre E, for the POWER 1 and 2 Study Groups. Efficacy and
safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1
infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised
trials. Lancet 2007;369(9568):1169-1178.
85.
Haubrich RH, Jiang H, Swanstrom R, Bates M, Katzenstein D, Petch L, Fletcher CV,
Fiscus SA, Gulick RM, for the AIDS Clinical Trials Group Protocol 359 Team. Nonnucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359. HIV
Clin Trials 2007;8(2)63-67.
Richard H. Haubrich, M.D.
Curriculum Vitae
Page 11
86.
Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, Pialoux G, Wilkin T,
Peeters M, Vingerhoets J, de Smedt G, Leopold L, Trefiglio R, Woodfall B, on behalf of
the DUET-1 study group. Efficacy and safety of TMC125 (etravirine) in treatmentexperienced HIV-1-infected patients in DUET-1: 24-week results from a randomised,
double-blind, placebo-controlled trial. Lancet 2007;370(9581):29-38.
87.
Haubrich R. Defining HIV susceptibility to new antiretroviral agents–darunavir. J Infect
Dis 2007;196(8):1125-1127.
88.
Best BM, Goicoechea M, Witt MD, Miller L, Daar ES, Diamond C, Tilles JG, Kemper CA,
Larsen R, Holland DT, Sun S, Jain S, Wagner G, Capparelli EV, McCutchan JA,
Haubrich RH, and the California Collaborative Treatment Group 578 Study Team. A
randomized controlled trial of therapeutic drug monitoring in treatment-naive and
experienced HIV-1-infected patients. J Acquir Immune Defic Syndr 2007;46(4):433-442.
89.
Goicoechea M, Haubrich R. Nelfinavir (Chapter 15). In: Dolin R, Masur H, Saag MS,
eds., AIDS Therapy. 3rd Ed. St. Louis, MO: Elsevier Science; 2008:327-340.
90.
Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, Witt M, Diamond C, Haubrich R,
Louie S; California Collaborative Treatment Group 578 Team. Greater tenofovir-associated
renal function decline with protease inhibitor-based versus nonnucleoside reversetranscriptase inhibitor-based therapy. J Infect Dis 2008;197(1):102-108.
91.
Koelsch KK, Liu L, Haubrich R, May S, Havlir D, Günthard HF, Ignacio CC, CamposSoto P, Little SJ, Shafer R, Robbins GK, D’Aquila RT, Kawano Y, Young K, Dao P, Spina
CA, Richman DD, Wong JK. Dynamics of total, linear nonintegrated, and integrated HIV-1
DNA in vivo and in vitro. J Infect Dis 2008;197(3):411-419.
92.
Haubrich R, Gubernick S, Yasothan U, Kirkpatrick P. Etravirine. Nat Rev Drug Discov
2008;7(4):287-288.
93.
Anderson JA, Jiang H, Ding X, Petch L, Journigan T, Fiscus SA, Haubrich R, Katzenstein
D, Swanstrom R, Gulick RM and the AIDS Clinical Trials Group Study 359 Protocol
Team. Genotypic susceptibility scores and HIV type 1 RNA responses in treatmentexperienced subjects with HIV type 1 infection. AIDS Res Hum Retroviruses 2008;
24(5):685-694.
94.
Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren
KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D,
Mellors JW and the AIDS Clinical Trials Group Study A5142 Team. Class-sparing
regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358(20):2095-2106.
(Drs. Riddler and Haubrich contributed equally to this article).
95.
Milefchik E, Leal MA, Haubrich R, Bozzette SA, Tilles JG, Leedom JM, McCutchan JA,
Larsen RA. Fluconazole alone or combined with flucytosine for the treatment of AIDSassociated cryptococcal meningitis. Med Mycol 2008;46(4):393-395.
96.
Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, Witt M, Diamond C, Haubrich R,
Louie S, and the CCTG 578 Team. Reply [to Letter from Crane et al.: Tenofovir-associated
decline in renal function]. J Infect Dis 2008;198(6):937-938.
Richard H. Haubrich, M.D.
Curriculum Vitae
Page 12
97.
Haubrich R, Soriano V, Lafeuillade A. Statements from the 15th International Symposium
on HIV and Emerging Infectious Diseases (ISHEID), Toulon, France, May 28-30, 2008.
HIV Clin Trials 2008;9(5):348-365.
98.
Kitahata MM, Rodriguez B, Haubrich R, Boswell S, Mathews WC, Lederman MM, Lober
WB, Van Rompaey SE, Crane HM, Moore RD, Bertram M, Kahn JO, Saag MS. Cohort
profile: the Centers for AIDS Research Network of Integrated Clinical Systems. Int J
Epidemiol 2008;37(5):948-955. PMC2597168
99.
Eron JJ Jr, Park JG, Haubrich R, Aweeka F, Bastow B, Pakes GE, Yu S, Wu H, Richman
DD and the ACTG 5126 Study Team. Predictive value of pharmacokinetics-adjusted
phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in
human immunodeficiency virus-infected subjects failing prior PI therapy. Antimicrob
Agents Chemother 2009; 53(6):2335-2341. PMC2687257
100. Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K,
Garren KW, Butcher DL, Rooney JF, Haas DW, Mellors JW, Havlir DV; AIDS Clinical
Trials Group (ACTG) A5142 Study Team. Metabolic outcomes in a randomized trial of
nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV
treatment. AIDS 2009;23(9):1109-1118.
101. Brumme ZL, John M, Carlson JM, Brumme CJ, Chan D, Brockman MA, Swenson LC, Tao
I, Szeto S, Rosato P, Sela J, Kadie CM, Frahm N, Brander C, Haas DW, Riddler SA,
Haubrich R, Walker BD, Harrigan PR, Heckerman D, Mallal S. HLA-associated immune
escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One 2009;4(8):
e6687. PMC2723923
102. May S, Gamst A, Haubrich R, Benson C, Smith DM. Pooled nucleic acid testing to
identify antiretroviral treatment failure during HIV infection. J Acquir Immune Defic Synd
2010;53(2): 194-201.
103. Smith DM, May SJ, Pérez-Santiago J, Strain MC, Ignacio CC, Haubrich RH, Richman
DD, Benson CA, Little SJ. The use of pooled viral load testing to identify antiretroviral
treatment failure. AIDS 2009;23(16):2151-2158.
104. Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina JM, Schechter M,
Peeters M, Picchio G, Vingerhoets J, Woodfall B, De Smedt G; and the DUET-1, DUET-2
study groups. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients:
pooled 48 week analysis of two randomized, controlled trials. AIDS 2009;23(17):22892300.
105. Minuto JJ, Haubrich R. Etravirine: a second-generation NNRTI for treatment-experienced
adults with resistant HIV-1 infection. Futur HIV Ther 2008;2(6):525-537.
106. Goicoechea M, Jain S, Bi L, Sun S, Smith G, Ha B, Richman D, Louie S, Haubrich R,
Treatment Group CC. Interlaboratory Measurement Differences in Intracellular Carbovir
Triphosphate Concentrations in HIV-Infected Patients: Sources of Variability in
Processing, Shipping, and Quantitation. J Clin Pharmacol 2009; Dec 1. [Epub ahead of
print].
Richard H. Haubrich, M.D.
Curriculum Vitae
Page 13
107. Asmuth DM, Goodrich J, Cooper DA, Haubrich R, Rajicic N, Hirschel B, Mayer H,
Valdez H. CD4+ T-cell restoration after 48 weeks in the Maraviroc treatment-experienced
Trials MOTIVATE 1 and 2. J Acquir Immune Defic Syndr [Epub ahead of print].
108. Aldous J, Haubrich R. Defining treatment failure in resource-rich settings. Curr Opin HIV
AIDS 2009;4(6):459-466.
109. Goicoechea M, Jain S, Bi L, Kemper C, Daar ES, Diamond C, Ha B, Flaherty J, Sun S,
Richman D, Louie S, Haubrich R, and the California Collaborative Treatment Group.
Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive
antiviral effect in HIV-1-infected patients. AIDS 2010;24(5):707-716.
110. John M, Heckerman D, James I, Park LP, Carlson JM, Chopra A, Gaudieri S, Nolan D,
Haas DW, Riddler SA, Haubrich R, Mallal S. Adaptive interactions between HLA and
HIV-1: highly divergent selection imposed by HLA class I molecules with common
supertype motifs. J Immunol 2010;184(8):4368-4377.
111. Best BM, Koopmans PP, Letendre SL, Capparelli EV, Rossi SS, Clifford DB, Collier AC,
Gelman BB, Mbeo G, McCutchan JA, Simpson DM, Haubrich R, Ellis R, Grant I; on
behalf of the CHARTER Group. Efavirenz concentrations in CSF exceed IC50 for wildtype HIV. J Antimicrob Chemother. 2010 Nov 23. [Epub ahead of print]
112.
van Zyl GU, Preiser W, Potschka S, Lundershausen AT, Haubrich R, Smith D. Pooling
Strategies to Reduce the Cost of HIV-1 RNA Load Monitoring in a Resource-Limited
Setting. Clin Infect Dis. 2011 Jan;52(2):264-70. PubMed PMID: 21288854.
113.
International HIV Controllers Study, Pereyra F, ...Haubrich R, …, Zhao M. The major
genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science.
2010 Dec 10;330(6010):1551-7. Epub 2010 Nov 4. PubMed PMID: 21051598.
114.
Katlama C, Clotet B, Mills A, Trottier B, Molina JM, Grinsztejn B, Towner W,
Haubrich R, Nijs S, Vingerhoets J, Woodfall B, Witek J. Efficacy and safety of
etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the
DUET-1 and DUET-2 trials. Antivir Ther. 2010;15(7):1045-52. PubMed PMID:
21041921.
115.
Hulgan T, Haubrich R, Riddler SA, Tebas P, Ritchie MD, McComsey GA, Haas DW,
Canter JA. European mitochondrial DNA haplogroups and metabolic changes during
antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS. 2011 Jan
2;25(1):37-47. PubMed PMID: 20871389; PubMed Central PMCID: PMC2995830.
116.
Brehm JH, Lalama CM, Hughes MD, Haubrich R, Riddler SA, Sluis-Cremer N, Mellors
JW; for the AIDS Clinical Trials Group Study A5142 Protocol Team. Failure of Initial
Therapy With Two Nucleosides and Efavirenz Is Not Associated With Early Emergence
of Mutations in the C-Terminus of HIV-1 Reverse Transcriptase. J Acquir Immune Defic
Syndr. 2011 Apr;56(4):344-348. PubMed PMID: 21350368.
117.
Grady BJ, Torstenson ES, McLaren PJ, DE Bakker PI, Haas DW, Robbins GK, Gulick
RM, Haubrich R, Ribaudo H, Ritchie MD. Use of biological knowledge to inform the
analysis of gene-gene interactions involved in modulating virologic failure with
efavirenz-containing treatment regimens in art-naïve actg clinical trials participants. Pac
Symp Biocomput. 2011:253-64. PubMed PMID: 21121053.
Richard H. Haubrich, M.D.
Curriculum Vitae
Page 14
118.
Simpson KN, Dietz B, Baran RW, Garren KW, Riddler SA, Bhor M, Haubrich RH.
Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy
based on ACTG 5142 trial data. Cost Eff Resour Alloc. 2011 May 8;9:5. PubMed PMID:
21548986; PubMed Central PMCID: PMC3117802.
119.
Yamamoto T, Price DA, Casazza JP, Ferrari G, Nason M, Chattopadhyay PK, Roederer
M, Gostick E, Katsikis PD, Douek DC, Haubrich R, Petrovas C, Koup RA. Surface
expression patterns of negative regulatory molecules identify determinants of virusspecific CD8+ T-cell exhaustion in HIV infection. Blood. 2011 May 5;117(18):4805-15.
Epub 2011 Mar 11. PubMed PMID: 21398582; PubMed Central PMCID: PMC3100691.
120.
Poon AF, Aldous JL, Mathews WC, Kitahata M, Kahn JS, Saag MS, Rodríguez B,
Boswell SL, Frost SD, Haubrich RH. Transmitted drug resistance in the CFAR network
of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral
load. PLoS One. 2011;6(6):e21189. Epub 2011 Jun 20. PubMed PMID: 21701595;
PubMed Central PMCID: PMC3118815.
121.
Taiwo B, Gallien S, Aga E, Ribaudo H, Haubrich R, Kuritzkes DR, Eron JJ Jr.
Antiretroviral Drug Resistance in HIV-1-Infected Patients Experiencing Persistent LowLevel Viremia During First-Line Therapy. J Infect Dis. 2011 Aug;204(4):515-20.
PubMed PMID: 21791652.
122.
Almeida CA, Bronke C, Roberts SG, McKinnon E, Keane NM, Chopra A, Kadie C,
Carlson J, Haas DW, Riddler SA, Haubrich R, Heckerman D, Mallal S, John M.
Translation of HLA-HIV Associations to the Cellular Level: HIV Adapts To Inflate CD8
T Cell Responses against Nef and HLA-Adapted Variant Epitopes. J Immunol. 2011 Sep
1;187(5):2502-13. Epub 2011 Aug 5. PubMed PMID: 21821798.
123.
Mugavero MJ, May M, Ribaudo HJ, Gulick RM, Riddler SA, Haubrich R, Napravnik S,
Abgrall S, Phillips A, Harris R, Gill MJ, de Wolf F, Hogg R, Günthard HF, Chêne G,
Dʼarminio Monforte A, Guest JL, Smith C, Murillas J, Berenguer J, Wyen C, Domingo
P, Kitahata MM, Sterne JA, Saag MS; on behalf of the AIDS Clinical Trial Group DACS
241 team AIDS Clinical Trial Group Study 5095 team AIDS Clinical Trial Group Study
5142 team and the Antiretroviral Cohort Collaboration. Comparative Effectiveness of
Initial Antiretroviral Therapy Regimens: ACTG 5095 and 5142 Clinical Trials Relative
to ART-CC Cohort Study. J Acquir Immune Defic Syndr. 2011 Aug 18. [Epub ahead of
print] PubMed PMID: 21857357.
124.
Haubrich RH, Riddler SA, Ribaudo H, Dirienzo AG, Klingman KL, Garren KW,
Butcher DL, Rooney JF, Havlir DV, Mellors JW; for the AIDS Clinical Trials Group
(ACTG) A5160 and A5142 Study Teams. Initial Viral Decay to Assess the Relative
Antiretroviral Potency of PI-, NNRTI- and NRTI-Sparing Regimens for First Line
Therapy of HIV Infection. AIDS. 2011 Sep 21. [Epub ahead of print] PubMed PMID:
21941167.
Richard H. Haubrich, M.D.
Curriculum Vitae
Page 15
125.
Haas DW, Kuritzkes DR, Ritchie MD, Amur S, Gage BF, Maartens G, Masys D, Fellay
J, Phillips E, Ribaudo HJ, Freedberg KA, Petropoulos C, Manolio TA, Gulick RM,
Haubrich R, Kim P, Dehlinger M, Abebe R, Telenti A; Workshop Pharmacogenomics-A
Path Towards Personalized HIV Care. Pharmacogenomics of HIV therapy: summary of a
workshop sponsored by the National Institute of Allergy and Infectious Diseases. HIV
Clin Trials. 2011 Sep-Oct;12(5):277-85. PubMed PMID: 22180526.
126.
Aldous JL, Pond SK, Poon A, Jain S, Qin H, Kahn JS, Kitahata M, Rodriguez B, Dennis
AM, Boswell SL, Haubrich R, Smith DM. Characterizing HIV Transmission Networks
Across the United States. Clin Infect Dis. 2012 Oct;55(8):1135-43. Epub 2012 Jul 10.
PubMed PMID: 22784872.
127.
Krishnan S, Schouten JT, Atkinson B, Brown T, Wohl D, McComsey GA, Glesby MJ,
Shikuma C, Haubrich R, Tebas P, Campbell TB, Jacobson DL. Metabolic Syndrome
Before and After Initiation of Antiretroviral Therapy in Treatment-Naïve HIV-Infected
Individuals. J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):381-389. PubMed PMID:
22828718; PubMed Central PMCID: PMC3480980.
128.
Carlson JM, Brumme CJ, Martin E, Listgarten J, Brockman MA, Le AQ, Chui C, Cotton
LA, Knapp DJ, Riddler SA, Haubrich R, Nelson G, Pfeifer N, Deziel CE, Heckerman D,
Apps R, Carrington M, Mallal S, Harrigan PR, John M, Brumme ZL; the International
HIV Adaptation Collaborative. Correlates of protective cellular immunity revealed by
analysis of population-level immune escape pathways in HIV-1. J Virol. 2012 Oct 10.
[Epub ahead of print] PubMed PMID: 23055555.
129.
Innes S, Schulte-Kemna E, Cotton MF, Zöllner EW, Haubrich R, Klinker H, Sun X, Jain
S, Edson C, van Niekerk M, Innes ER, Rabie H, Browne SH. Biceps Skin-Fold Thickness
May Detect and Predict Early Lipoatrophy in HIV-Infected Children. Pediatr Infect Dis J.
2012 Dec 17. [Epub ahead of print] PubMed PMID: 23249919.
130.
Innes S, Cotton MF, Haubrich R, Conradie MM, van Niekerk M, Edson C, Rabie H,
Jain S, Sun X, Zöllner EW, Hough S, Browne SH. High prevalence of lipoatrophy in prepubertal South African children on antiretroviral therapy: a cross-sectional study. BMC
Pediatr. 2012 Nov 23;12:183. doi: 10.1186/1471-2431-12-183. PubMed PMID:
23176441; PubMed Central PMCID: PMC3584923.
131.
Carlson JM, Brumme CJ, Martin E, Listgarten J, Brockman MA, Le AQ, Chui CK,
Cotton LA, Knapp DJ, Riddler SA, Haubrich R, Nelson G, Pfeifer N, Deziel CE,
Heckerman D, Apps R, Carrington M, Mallal S, Harrigan PR, John M, Brumme ZL;
International HIV Adaptation Collaborative. Correlates of protective cellular immunity
revealed by analysis of population-level immune escape pathways in HIV-1. J Virol.
2012 Dec;86(24):13202-16. doi: 10.1128/JVI.01998-12. Epub 2012 Oct 10. PubMed
PMID: 23055555; PubMed Central PMCID: PMC3503140.
132.
Gianella S, Smith DM, Vargas MV, Little SJ, Richman DD, Daar ES, Dube MP, Zhang
F, Ginocchio CC, Haubrich RH, Morris SR; the CCTG 592 Team. Shedding of HIV and
Human Herpesviruses in the Semen of Effectively Treated HIV-1-Infected Men Who
Have Sex With Men. Clin Infect Dis. 2013 May 22. [Epub ahead of print] PubMed
PMID: 23595831.
Richard H. Haubrich, M.D.
Curriculum Vitae
Page 16
Published Abstracts
1.
Haubrich RH, McCutchan JA, Caralli V, Spector SA, Jacobsen C, Kang C, Merritt J.
Safety and immunogenicity of a monoclonal anti-idiotype antibody (3C9) plus SAF-m
adjuvant for HIV-infected patients. J Cell Biochem 1993; Keystone Symposia, Suppl
17E:79.
2.
Haubrich R, Burger HU, Beattie D, Donatacci L, Salgo MP, and the NV14256 Study
Team. Saquinavir plus zalcitabine vs saquinavir or zalcitabine monotherapy in HIVinfected patients discontinuing or intolerant to zidovudine: results of a randomized, double
blind trial. AIDS 1996;10(Suppl 1,2):S17.
3.
Haubrich R, Kemper C, Witt M, Keiser P, Dubé M, Forthal D, Currier J, Seefried E,
Rigby A, Richman D, Hellmann N, Heilek G, Lie Y, McCutchan JA, and the CCTG.
Differences in protease inhibitor (PI) phenotypic susceptibility after failure of the first PIcontaining regimen. Antivir Ther 2000;4(Suppl 1):55. Abstract 80.
4.
Haubrich R, Whitcomb J, Keiser P, Kemper C, Witt M, Dubé M, Forthal D, Leibowitz M,
Hwang J, Rigby A, Hellmann N, McCutchan JA, Richman D, and the CCTG. Nonnucleoside reverse transcriptase inhibitor viral hypersensitivity is common and improves
short-term virological response. Antivir Ther 2000;5(Suppl 3):69. Abstract 87.
5.
Haubrich R, Keiser P, Kemper C, Witt M, Leedom J, Forthal D, Leibowitz M, Hwang J,
Seefried E, McCutchan JA, Hellmann N, Richman D, and the CCTG Study Team. CCTG
575: a randomized, prospective study of phenotype testing versus standard of care for
patients failing antiretroviral therapy. Antivir Ther 2001;6(Suppl 1):63. Abstract 80.
6.
Hellmann NS, Wrin T, Bates M, Grant R, Hicks C, Haubrich R, Petropoulos CJ.
Modelling the effect of HIV replication capacity on treatment outcomes. Antivir Ther 2002;
7(Suppl 1):S70. Abstract 63.
7.
Haubrich R, Wrin T, Hellmann N, McCutchan JA, Keiser P, Kemper C, Witt M, Leedom
J, Forthal D, Richman D, and the CCTG. Replication capacity as a predictor of
immunological and virological benefit despite virological failure of an antiretroviral
regimen. Antivir Ther 2002;7(Suppl 1):S133. Abstract 121.
8.
Becker MI, Haubrich R, Wesselman CW, Garrett L, Lee SY, Millard D, Baxter JD. HIV-1
genotypic resistance in treatment-naive subjects enrolled in an observational trial (GAIN).
Antivir Ther 2002;7(Suppl 1):S175. Abstract 161.
9.
Miller L, McCutchan JA, Keiser P, Kemper C, Witt M, Leedom J, Forthal D, Hellmann N,
Richman D, Seefried E, Rigby A, Haubrich R, and the California Collaborative Treatment
Group. Accumulation of antiretroviral resistance in treatment-experienced patients: the
impact of medication adherence. Antivir Ther 2003;8(Suppl 1):S167. Abstract 151.
10.
Haubrich R, Hernandez J, Bates M, Thompson M, Margolis D, Pappa K, Yau L, Schooley
R. Determinants of replication capacity (RC) in HIV-1 isolates from antiretroviral (ART)experienced adults failing a PI-based regimen, and relationship of RC with HIV-1 RNA
and CD4 counts. Antivir Ther 2004;9(4):S162. Abstract 146.
Richard H. Haubrich, M.D.
Curriculum Vitae
Page 17
11.
Haubrich RH, Riddler SA, DiRienzo AG, Peeples L, Klingman KL, Garren KW, George
T, Rooney JF, Brizz B, Havlir D, Mellors JW, and the AIDS Clinical Trials Group 5142
Study Team. Drug resistance at virological failure in a randomized, Phase III trial of
NRTI-, PI- and NNRTI-sparing regimens for initial treatment of HIV-1 infection (ACTG
5142). Antivir Ther 2007;12(Suppl 1):S66. Abstract 57.
12.
Jain S, Mathews C, Saag M, Kitahata M, Rodriguez B, Kahn J, Boswell S, Lober WB,
Lederman M, Sun S, Frost S, Haubrich RH, and the CNICS Study Team. Increasing
prevalence of triple-class-experienced patients at six US sites: data from the CNICS
(CFAR Network of Integrated Clinical Systems) cohort. Antivir Ther 2007;12(Suppl
1):S71. Abstract 62.
13.
Frost SDW, Mathews C, Saag M, Kitahata M, Rodriguez B, Kahn J, Boswell S, Lober WB,
Lederman M, Sun S, Poon AFY, Jain S, Haubrich RH, and the CNICS Study Team.
Representing complex regimen data in the CNICS (CFAR Network of Integrated Clinical
Systems) cohort. Antivir Ther 2007;12(Suppl 1):S168. Abstract 153.
14.
Brehm J, Sheen CW, Hughes M, Lalama C, Haubrich R, Riddler S, Sluis-Cremer N and
Mellors J. Virologic failure of regimens containing two NRTIs plus efavirenz is not
associated with the selection of mutations in the connection or RNase H domains of reverse
transcriptase. Antivir Ther 2009; 14 (Suppl 1): A34. Abstract 32.
15.
Aldous JL, Jain S, Sun S, Mathews C, Kitahata M, Kahn J, Saag M, Rodriguez B, Boswell
S, Frost SD, Haubrich RH and the CNICS 002 Study Team. Increasing prevalence of
triple-class antiretroviral experienced patients is not associated with virologic failure: data
from the CFAR network of integrated clinical systems (CNICS) cohort. Antivir Ther 2009;
14 (Suppl 1): A84. Abstract 73.
Recent Presented Abstracts
1.
Aldous J, Jain S, Sun S, Mathews C, Kitahata M, Kahn J, Saag M, Rodriquez B, Boswell S,
Haubrich R, and the CNICS 002 Study Group. Decreasing Prevalence of Drug Resistance
Mutations over a 7 Year Period in the CFAR Network of Integrated Clinical Systems. 17th
Conference on Retroviruses and Opportunistic Infections; February 16-19, 2010; San
Francisco, CA. Abstract 585.
2.
Poon A, Aldous J, Mathews C, Kitahata M, Kahn J, Saag M, Rodriquez B, Boswell S, Frost
S, Haubrich R, and the CNICS 002 Study Group. Association with Transmission of
M184V/I and a Reduced Viral Load in Therapy-Naïve Patients in the CFAR Network of
Integrated Clinical Systems (CNICS) Cohort 17th Conference on Retroviruses and
Opportunistic Infections; February 16-19, 2010; San Francisco, CA. Abstract 583
3.
Goicoechea M, Rieg G, Dube M, Kerkar S, Schneider S, Kemper C, Diamond C, Jain S,
Sun S, Hermes A, Daar E, Haubrich R, California Collaborative Treatment Group. Faster
early viral decline with raltegravir (RAL) + lopinavir/ritonavir (LPV/r) vs. efavirenz
(EFV)/ tenofovir disoproxil fumarate (TDF)/ emtricitabine (FTC) in antiretroviral-naive
patients: CCTG 589. XVIII International AIDS Conference; July 18- 23, 2010; Vienna,
Austria. Abstract THPE0068.
Richard H. Haubrich, M.D.
Curriculum Vitae
Page 18
4.
Rodriguez B, Lanzkron S, Haywood C, Kitahata M, Eron J, Moore R, Kahn J, Haubrich R,
Matthews W, Kalayjian R, Saag M, Lederman M. Sickle cell disease is associated with a
decreased probability of HIV infection among black patients in the United States. XVIII
International AIDS Conference; July 18- 23, 2010; Vienna, Austria. Abstract TUPE0072.
5.
Potschka S, Lundershausen A, Haubrich R, Smith D, Preiser W, van Zy G. Use of clinical
criteria with HIV RNA viral load pooling reduces the cost of monitoring antiretroviral
therapy (ART) in low- to middle- income countries. XVIII International AIDS Conference;
July 18- 23, 2010; Vienna, Austria. Abstract TUPE0109.
6.
Huang J, Hughes M, Riddler S, Haubrich R, AIDS Clinical Trials Group 5142 Study
Team. Effects of randomized regimen and nucleoside reverse transcriptase inhibitor
(NRTI) selection on 96 week bone mineral density (BMD): results from ACTG 5142.
XVIII International AIDS Conference; July 18- 23, 2010; Vienna, Austria. Abstract
WEAB0304.
7.
Goicoechea M, Zheng Y, Hughes M, Riddler S, Neely M, Haas D, Louie S, Haubrich R.
Antiretroviral regimen and pharmacogenetic determinants of tenofovir-associated change
in creatinine clearance in ACTG protocol A5142. XVIII International AIDS Conference;
July 18- 23, 2010; Vienna, Austria. Abstract WEAB0305.
8.
Miller L, Minuto J, Jain S, Mai T, Diamond C, Larsen R, Kemper C, Sun S, Diep D,
Haubrich R and California Cooperative Treatment Group (CCTG) 587 Investigators. A
Multi-Center Prospective Investigation of Risk Factors for Community-Associated
Methicillin Resistant Staphylococcus aureus (CA-MRSA) Infection in HIV-Infected
Persons. 18th Conference on Retroviruses and Opportunistic Infections, Boston, February
27-March 2, 2011. Abstract 900.
9.
Ribaudo H, Smith K, Robbins G, Flexner C, Haubrich R, Chen Y, Fischl M, Riddler S and
Gulick R. Race Differences in the Efficacy of Initial ART on HIV Infection in Randomized
Trials Undertaken by ACTG. 18th Conference on Retroviruses and Opportunistic
Infections, Boston, February 27-March 2, 2011. Abstract 50.
10. Aldous J, Poon A, Kosakovsky Pond S, Jain S, Qin H, Kahn J, Kitahata M, Rodriguez B,
Haubrich R, and Smith D. 18th Identifying HIV Transmission Networks in the CNICS:
Implications for the Study of Transmission in Women and Minorities in a Large Clinical
Cohort. 18th Conference on Retroviruses and Opportunistic Infections, Boston, February
27-March 2, 2011. Abstract 1045.
11. McLaren P, Ribaudo H, Daar E, Robbins G, Haubrich R, Acosta E, Morse G, de Bakker P,
Haas D, and ACTG. Whole Genome Association Study of Viral Failure with EFV- and/or
ABC-containing Regimens in ACTG Studies. 18th Conference on Retroviruses and
Opportunistic Infections, Boston, February 27-March 2, 2011. Abstract 477.
12. Bowman V, Rieg G, Jain S, Goicoechea M, Dube M, Kerkar S, Schneider S, Kemper C,
Diamond C, Sun S, Hermes A, Bailey K, Daar E, Haubrich R, California Collaborative
Treatment Group. 48 week results of a pilot randomized study of an nucleoside reverse
transcriptase inhibitor (NRTI)-sparing regimen of raltegravir (RAL) + lopinavir/ritonavir
(LPV/r) versus efavirenz/tenofovir disoproxil fumarate /emtricitabine (EFV/TDF/FTC) in
antiretroviral naïve subjects. 6th IAS Conference on HIV Pathogenesis, Treatment and
Prevention, Rome, Italy, July 17-20, 2011. Abstract CDB336.
Richard H. Haubrich, M.D.
Curriculum Vitae
Page 19
13. Innes S, van Niekerk M, Rabie H, Cotton M, Haubrich R, Browne S. Prevalence and risk
factors for lipoatrophy among pre-pubertal African children on HAART. 6th IAS
Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, July 17-20,
2011. Abstract CDB430.
14. Innes S, Cotton M, Haubrich R, Eagar R, Edson C, Jain S, Sun X, Zoellner E, and Browne
S. High Prevalence of Objectively Verified Clinical Lipoatrophy in Pre-pubertal Children
Is Associated with Stavudine—the Clock Is Ticking: Sub-Saharan Africa. 19th Conference
on Retroviruses and Opportunistic Infections, Seattle, March 5-8, 2012. Abstract 972.
15. Achenbach C, Cole S, Kahn J, Mugavero M, Crane H, Eron J, Moore R, Haubrich R, Saag
M, and Kitahata. Incidence and Predictors of NHL among HIV+ Patients on Suppressive
ART. 19th Conference on Retroviruses and Opportunistic Infections, Seattle, March 5-8,
2012. Abstract 131.
16. Larsen R, Sanchez A, Haubrich R, and Daar E. A Phase I Safety Study of Angiotensin 1-7
(TXA127) in Persons with HIV Viral Control but Poor Immune Reconstitution. 19th
Conference on Retroviruses and Opportunistic Infections, Seattle, March 5-8, 2012.
Abstract 602.
17.
Zheng L, Mellors J, Gulick R, Riddler S, Haubrich R, and Hughes M. Neither Pretreatment CD4+ Cell Count nor HIV-1 RNA Is Associated with Emergence of Drug
Resistance at Virologic Failure on Efavirenz + NRTI: Randomized ACTG Studies. 19th
Conference on Retroviruses and Opportunistic Infections, Seattle, March 5-8, 2012.
Abstract 705.
18. Tashima K, Mollan K, Na L, Gandhi R, Klingman K, Fichtenbaum C, Andrade A, Johnson
V, Eron J, Haubrich R. Baseline characteristics and acceptance of regimens recommended
by an expert panel in ACTG A5241 OPTIONS, a randomized salvage HIV therapy trial.
20th Conference on Retroviruses and Opportunistic Infections, Atlanta, March 3-6, 2013.
Abstract 557.
19. Tashima ., Smeaton L, Andrade A, Eron J, Fichtenbaum C. Gandhi R, Johnson V,
Klingman K, Hollabaugh K, Haubrich R. Omitting NRTIs from ARV regimens is not
inferior to adding NRTIs in treatment experienced HIV+ subjects failing a PI regimen: the
ACTG OPTIONS study. 20th Conference on Retroviruses and Opportunistic Infections,
Atlanta, March 3-6, 2013. Abstract 153LB (late breaker Oral presentation).
20. McKinnon J, Lalama C, Riddler S, Haubrich R, Hughes M, Vagratian D, Mellors J.
Residual viremia detected by single copy plasma HIV-RNA assay as an early predictor of
virologic failure. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta,
March 3-6, 2013. Abstract 603.
21. Grant P, Kitch D, McComsey G, Dube M, Haubrich R, Huang J, Riddler S, Tebas P,
Zolopa A, Brown T. Lower baseline CD4 is associated with greater loss of bone mineral
density (BMD) after antiretroviral therapy (ART) initiation. 20th Conference on
Retroviruses and Opportunistic Infections, Atlanta, March 3-6, 2013. Abstract 823.
Richard H. Haubrich, M.D.
Curriculum Vitae
Page 20
22. Ellis R, Vaida F, Letendre S, Haubrich R, Heaton R, McCutchan A, Cherner M, Umlauf
A, Sacktor N, Clifford D. A Randomized Controlled Trial of a Central Nervous Systemtargeted Strategy for HIV-associated Neurocognitive Disorders. 20th Conference on
Retroviruses and Opportunistic Infections, Atlanta, March 3-6, 2013. Abstract 20.
23. Haubrich R, Jain S, Perez-Heydrich, C, Hurt P, Morris S, Sun S, Napravnik S, Crane H,
Emch M, Eron J. Geospatial and Individual Factors are Associated with High-risk
Transmission Behavior among HIV+ Subjects in Care: Data from CNICS. 20th Conference
on Retroviruses and Opportunistic Infections, Atlanta, March 3-6, 2013. Abstract 1076.
24. Weibel S, Smith D, Vargas M, Little, Richman D, Daar E, Dube M, Ginocchio C,
Haubrich R, Morris S. Shedding of HIV and Human Herpesviruses in the Semen of
Effectively Treated HIV+ Men. 20th Conference on Retroviruses and Opportunistic
Infections, Atlanta, March 3-6, 2013. Abstract 1079.